Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia

International Journal of Cancer

Volumn 94, Issue 4, 2001, Pages 564-571

  Blumenthal, Rosalyn D ^a   Taylor, Alice ^a   Osorio, Lou ^a   Ochakovskaya, Rita ^a   Raleigh, Jim A ^b   Papadopoulou, Maria ^c   Bloomer, William D ^c   Goldenberg, David M ^a  

^a GARDEN STATE CANCER CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c EVANSTON HOSPITAL   (United States)

Author keywords

Cytotoxin; Hypoxia; Radioimmunotherapy (RAIT); Tumor growth; Xenograft

Indexed keywords

CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CYTOTOXIN; IMMUNOGLOBULIN G; TIRAPAZAMINE; TRACER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SIZE; CELL HYPOXIA; COLON TUMOR; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OXYGEN ELECTRODE; OXYGEN TISSUE LEVEL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME; TUMOR XENOGRAFT;

ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; CARCINOEMBRYONIC ANTIGEN; CELL HYPOXIA; COMBINED MODALITY THERAPY; CYTOTOXINS; DRUG TOXICITY; FEMALE; HUMANS; IMIDAZOLES; IMMUNOGLOBULIN G; MICE; MICE, NUDE; MICROELECTRODES; NEOPLASM TRANSPLANTATION; NEOPLASMS; OXYGEN; QUINOLINES; RADIATION-SENSITIZING AGENTS; RADIOIMMUNOTHERAPY; TIME FACTORS; TRIAZINES; TUMOR CELLS, CULTURED;

EID: 0035889659     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1500     Document Type: Article

References (59)

1. Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts
2. Radioimmunotherapy and fractionated radiotherapy of human colon cancer liver metastases in nude mice
3. 131I-labeled monoclonal antibody PAM4
4. Radioimmunotherapy using iodine-131, ytrium-90, or rhenium-188-labeled IgG and fragments in nude mice bearing well established or micrometastatic colonic tumors
5. Radioimmunotherapy of solid tumors: A review "of mice and men"
6. Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies
7. Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions
8. Multimodal experimental therapy of a s.c. colonic xenograft using radioimmunotherapy (RAIT) and chemotherapy
9. Synergy of taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: Efficacy and toxicity in breast cancer xenografts
10. Vascular lesions following radiation
11. Suppression of tumor vascular activity by radioantibody therapy: Implications for multiple cycle treatments
12. 2) during accelerated radiotherapy of head and neck carcinoma
13. 2 measured by EPR oximetry in human tumor xenografts
14. An estimation of changes in the proportion and absolute numbers of hypoxic cells after irradiation of transplanted C3H mouse mammary tumors
15. Radiation-induced reoxygenation in the SCCVII murine tumor: Evidence for a decrease in oxygen consumption and an increase in tumour perfusion
16. Effects of carbogen plus fractionated irradiation on KHT tumor oxygenation
17. Changes in blood perfusion after irradiation of a human squamous cell carcinoma xenograft tumor line
18. Enhancement of radiation-induced tumor cell killing by the hypoxic cell cytotoxin SR4233
19. Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma
20. Single arm, open label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme
21. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinoma: A phase II study
22. Phase II study of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer
23. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation [see comments]
24. 4-[3-(2-Nitro-1-Imidazolyl)propylamino]7-chloroquinoline hydrochloride (NLCQ-1). A novel bioreductive agent with enhanced hypoxic selectivity
25. Enhancement of the antitumor effect of taxol by the bioreductive compound NLCQ-1. Comparison with tirapazamine
26. NLCQ-1, a novel hypoxic cytotoxin: Potentiation of melphalan, cisDDP and cyclophosphamide in vivo
27. 131I-labeled antibody and the hypoxic cytotoxin SR 4233 in vitro and in vivo appears in Radiat
28. The hypoxic cytotoxin SR4233 increases the effectiveness of radioimmunotherapy in mice with human non-Hodgkin's lymphoma xenografts
29. Oxygen concentrations in six human tumor xenografts
30. Hypoxic fractions in xenografted human colon tumors
31. A new human tumor serially transplantable in the golden hamster
32. Characterization of second-generation monoclonal antibodies against carcinoembryonic antigen
33. Clinical evaluation of tumor targeting with a high-affinity anti-carcinoembryonic antigen specific murine monoclonal antibody, MN-14
34. Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody
35. Murine monoclonal antibodies raised against human non-small cell carcinoma of the lung: Specificity and tumor targeting
36. A method of trace radioiodination of proteins for immunologic purposes
37. 14C-Misonidazole as a probe for hypoxic cells in a murine tumor model
38. Binding of 3H-Misonidazole to solid human tumors as a measure of tumor hypoxia
39. Changes in tumor hypoxia measured with a double hypoxic marker technique
40. Changes in tumor vascular permeability in response to experimental radioimmunotherapy: A comparative study of 11 xenografts
41. Measurement of human tumor oxygenation status by a polarographic needle electrode
42. The histological structure of some human lung cancers and the possible implications for radiotherapy
43. Concentrations of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy
44. The effect of hypoxia on the growth and radiation response of mammalian cells in culture
45. The hypoxic cell: A target for selective cancer therapy - Eighteenth Bruce F. Cain Memorial Award Lecture
46. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors
47. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin
48. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: Relationship to tumor hypoxia
49. Relationship between radiobiological hypoxia in tumors and electrode measurements of tumor oxygenation
50. 3H]misonidazole binding and paired survival assay
51. Quantitative and qualitative effects of experimental radioimmunotherapy on tumor vascular permeability
52. Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: Retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial
53. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunotherapy: Doxorubicin potentiates the therapeutic efficacy of radio-labeled antibodies in a radioresistant tumor type
54. Enhanced antitumor activity of combination radioimmunotherapy (1311-labeled monoclonal antibody A33) with chemotherapy (fluorouracil)
55. A modeling approach for quantifying tumor hypoxia with [F-18]fluoromisonidazole PET time-activity data
56. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix
57. Radioiodinated azomycin pyranoside (IAZP): A novel non-invasive marker for the assessment of tumor hypoxia
58. Radioiodinated 1-(2-fluoro-4-iodo-2,4-dideoxy-beta-L-xylopyranosyl)-2-nitroimidazole: A novel probe for the noninvasive assessment of tumor hypoxia
59. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia